View Item 

Show simple item record

Patterns of benzodiazepine underdosing in the Established Status Epilepticus Treatment Trial
dc.contributor.authorSathe, Abhishek G.
dc.contributor.authorUnderwood, Ellen
dc.contributor.authorColes, Lisa D.
dc.contributor.authorElm, Jordan J.
dc.contributor.authorSilbergleit, Robert
dc.contributor.authorChamberlain, James M.
dc.contributor.authorKapur, Jaideep
dc.contributor.authorCock, Hannah R.
dc.contributor.authorFountain, Nathan B.
dc.contributor.authorShinnar, Shlomo
dc.contributor.authorLowenstein, Daniel H.
dc.contributor.authorRosenthal, Eric S.
dc.contributor.authorConwit, Robin A.
dc.contributor.authorBleck, Thomas P.
dc.contributor.authorCloyd, James C.
dc.date.accessioned2021-04-06T02:14:52Z
dc.date.available2022-04-05 22:14:50en
dc.date.available2021-04-06T02:14:52Z
dc.date.issued2021-03
dc.identifier.citationSathe, Abhishek G.; Underwood, Ellen; Coles, Lisa D.; Elm, Jordan J.; Silbergleit, Robert; Chamberlain, James M.; Kapur, Jaideep; Cock, Hannah R.; Fountain, Nathan B.; Shinnar, Shlomo; Lowenstein, Daniel H.; Rosenthal, Eric S.; Conwit, Robin A.; Bleck, Thomas P.; Cloyd, James C. (2021). "Patterns of benzodiazepine underdosing in the Established Status Epilepticus Treatment Trial." Epilepsia 62(3): 795-806.
dc.identifier.issn0013-9580
dc.identifier.issn1528-1167
dc.identifier.urihttps://hdl.handle.net/2027.42/167123
dc.description.abstractObjectiveThis study was undertaken to describe patterns of benzodiazepine use as first‐line treatment of status epilepticus (SE) and test the association of benzodiazepine doses with response to second‐line agents in patients enrolled in the Established Status Epilepticus Treatment Trial (ESETT).MethodsPatients refractory to an adequate dose of benzodiazepines for the treatment of SE were enrolled in ESETT. Choice of benzodiazepine, doses given prior to administration of second‐line agent, route of administration, setting, and patient weight were characterized. These were compared with guideline‐recommended dosing. Logistic regression was used to determine the association of the first dose of benzodiazepine and the cumulative benzodiazepine dose with the response to second‐line agent.ResultsFour hundred sixty patients were administered 1170 doses of benzodiazepines (669 lorazepam, 398 midazolam, 103 diazepam). Lorazepam was most frequently administered intravenously in the emergency department, midazolam intramuscularly or intravenously by the emergency medical services personnel, and diazepam rectally prior to ambulance arrival. The first dose of the first benzodiazepine (N = 460) was lower than guideline recommendations in 76% of midazolam administrations and 81% of lorazepam administrations. Among all administrations, >85% of midazolam and >76% of lorazepam administrations were lower than recommended. Higher first or cumulative benzodiazepine doses were not associated with better outcomes or clinical seizure cessation in response to second‐line medications in these benzodiazepine‐refractory seizures.SignificanceBenzodiazepines as first‐line treatment of SE, particularly midazolam and lorazepam, are frequently underdosed throughout the United States. This broad and generalizable cohort confirms prior single site reports that underdosing is both pervasive and difficult to remediate. (ESETT ClinicalTrials.gov identifier: NCT01960075.)
dc.publisherWiley Periodicals, Inc.
dc.subject.otherESETT
dc.subject.otherbenzodiazepine dose
dc.subject.otherdiazepam
dc.subject.otherlorazepam
dc.subject.othermidazolam
dc.titlePatterns of benzodiazepine underdosing in the Established Status Epilepticus Treatment Trial
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelMedicine (General)
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/167123/1/epi16825_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/167123/2/epi16825.pdf
dc.identifier.doi10.1111/epi.16825
dc.identifier.sourceEpilepsia
dc.identifier.citedreferenceAnderson M, Tambe P, Sammons H, Mulla H, Cole R, Choonara I. Pharmacokinetics of buccal and intranasal lorazepam in healthy adult volunteers. Eur J Clin Pharmacol. 2012; 68 ( 2 ): 155 – 9.
dc.identifier.citedreferenceMaglalang PD, Rautiola D, Siegel RA, Fine JM, Hanson LR, Coles LD, et al. Rescue therapies for seizure emergencies: new modes of administration. Epilepsia. 2018; 59 ( Suppl 2 ): 207 – 15.
dc.identifier.citedreferenceBraun J, Gau E, Revelle S, Byrne L, Kumar A. Impact of non‐guideline‐based treatment of status epilepticus. J Neurol Sci. 2017; 382: 126 – 30.
dc.identifier.citedreferenceRao SK, Mahulikar A, Ibrahim M, Shah A, Seraji‐Bozorgzad N, Mohamed W. Inadequate benzodiazepine dosing may result in progression to refractory and non‐convulsive status epilepticus. Epileptic Disord. 2018; 20 ( 4 ): 265 – 9.
dc.identifier.citedreferenceKellinghaus C, Rossetti AO, Trinka E, Lang N, May TW, Unterberger I, et al. Factors predicting cessation of status epilepticus in clinical practice: data from a prospective observational registry (SENSE). Ann Neurol. 2019; 85 ( 3 ): 421 – 32.
dc.identifier.citedreferenceTrau SP, Sterrett EC, Feinstein L, Tran L, Gallentine WB, Tchapyjnikov D, et al. Institutional pediatric convulsive status epilepticus protocol decreases time to first and second line anti‐seizure medication administration. Seizure. 2020; 81: 263 – 8.
dc.identifier.citedreferenceVasquez A, Gaínza‐Lein M, Abend NS, Amengual‐Gual M, Anderson A, Arya R, et al. First‐line medication dosing in pediatric refractory status epilepticus. Neurology. 2020; 95 ( 19 ): e2683 – 96.
dc.identifier.citedreferenceGuterman EL, Sanford JK, Betjemann JP, Zhang LI, Burke JF, Lowenstein DH, et al. Prehospital midazolam use and outcomes among patients with out‐of‐hospital status epilepticus. Neurology. 2020; 95 ( 24 ): e3203 – 12.
dc.identifier.citedreferenceSathe AG, Tillman H, Coles LD, Elm JJ, Silbergleit R, Chamberlain J, et al. Underdosing of benzodiazepines in patients with status epilepticus enrolled in established status epilepticus treatment trial. Acad Emerg Med. 2019; 26 ( 8 ): 940 – 3.
dc.identifier.citedreferenceAlldredge BK, Gelb AM, Isaacs SM, Corry MD, Allen F, Ulrich S, et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out‐of‐hospital status epilepticus. N Engl J Med. 2001; 345 ( 9 ): 631 – 7.
dc.identifier.citedreferenceSilbergleit R, Durkalski V, Lowenstein D, Conwit R, Pancioli A, Palesch Y, et al. Intramuscular versus intravenous therapy for prehospital status. N Engl J Med. 2012; 366 ( 7 ): 591 – 600.
dc.identifier.citedreferenceGaínza‐Lein M, Fernández IS, Ulate‐Campos A, Loddenkemper T, Ostendorf AP. Timing in the treatment of status epilepticus: from basics to the clinic. Seizure. 2019; 68: 22 – 30.
dc.identifier.citedreferenceOstendorf AP, Merison K, Wheeler TA, Patel AD. Decreasing seizure treatment time through quality improvement reduces critical care utilization. Pediatr Neurol. 2018; 85: 58 – 66.
dc.identifier.citedreferenceGaínza‐Lein M, Sánchez Fernández I, Jackson M, Abend NS, Arya R, Brenton JN, et al. Association of time to treatment with short‐term outcomes for pediatric patients with refractory convulsive status epilepticus. JAMA Neurol. 2018; 75 ( 4 ): 410 – 8.
dc.identifier.citedreferenceLewena S, Young S. When benzodiazepines fail: how effective is second line therapy for status epilepticus in children? Emerg Med Australas. 2006; 18 ( 1 ): 45 – 50.
dc.identifier.citedreferenceBetjemann JP, Lowenstein DH. Status epilepticus in adults. Lancet Neurol. 2015; 14 ( 6 ): 615 – 24.
dc.identifier.citedreferenceChin RFM, Verhulst L, Neville BGR, Peters MJ, Scott RC. Inappropriate emergency management of status epilepticus in children contributes to need for intensive care. J Neurol Neurosurg Psychiatry. 2004; 75 ( 11 ): 1584 – 8.
dc.identifier.citedreferenceChin RFM, Neville BGR, Peckham C, Wade A, Bedford H, Scott RC, et al. Treatment of community‐onset, childhood convulsive status epilepticus: a prospective, population‐based study. Lancet Neurol. 2008; 7 ( 8 ): 696 – 703.
dc.identifier.citedreferenceMadžar D, Geyer A, Knappe RU, Gollwitzer S, Kuramatsu JB, Gerner ST, et al. Association of seizure duration and outcome in refractory status epilepticus. J Neurol. 2016; 263 ( 3 ): 485 – 91.
dc.identifier.citedreferenceUppal P, Cardamone M, Lawson JA. Outcomes of deviation from treatment guidelines in status epilepticus: a systematic review. Seizure. 2018; 58: 147 – 53.
dc.identifier.citedreferenceEriksson K, Metsaranta P, Huhtala H, Auvinen A, Kuusela A‐L, Koivikko M, et al. Treatment delay and the risk of prolonged status epilepticus. Neurology. 2005; 65: 1316 – 8.
dc.identifier.citedreferenceKapur J, Macdonald RL. Rapid seizure‐induced reduction of benzodiazepine and Zn2+ sensitivity of hippocampal dentate granule cell GABAA receptors. J Neurosci. 1997; 17 ( 19 ): 7532 – 40.
dc.identifier.citedreferenceMazarati AM, Baldwin RA, Sankar R, Wasterlain CG. Time‐dependent decrease in the effectiveness of antiepileptic drugs during the course of self‐sustaining status epilepticus. Brain Res. 1998; 814 ( 1–2 ): 179 – 85.
dc.identifier.citedreferenceNaylor DE, Liu H, Wasterlain CG. Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci. 2005; 25 ( 34 ): 7724 – 33.
dc.identifier.citedreferenceGoodkin HP, Joshi S, Mtchedlishvili Z, Brar J, Kapur J. Subunit‐specific trafficking of GABA(A) receptors during status epilepticus. J Neurosci. 2008; 28 ( 10 ): 2527 – 38.
dc.identifier.citedreferenceGoodkin HP, Kapur J. The impact of diazepam’s discovery on the treatment and understanding of status epilepticus. Epilepsia. 2009; 50 ( 9 ): 2011 – 8.
dc.identifier.citedreferenceGoodkin HP, Yeh J‐L, Kapur J. Status epilepticus increases the intracellular accumulation of GABAA receptors. J Neurosci. 2005; 25 ( 23 ): 5511 – 20.
dc.identifier.citedreferencePal S, Sun D, Limbrick D, Rafiq A, DeLorenzo RJ. Epileptogenesis induces long‐term alterations in intracellular calcium release and sequestration mechanisms in the hippocampal neuronal culture model of epilepsy. Cell Calcium. 2001; 30: 285 – 96.
dc.identifier.citedreferenceWasterlain CG, Naylor DE, Liu H, Niquet J, Baldwin R. Trafficking of NMDA receptors during status epilepticus: therapeutic implications. Epilepsia. 2013; 54: 78 – 80.
dc.identifier.citedreferenceBorris DJ, Bertram EH, Kapur J. Ketamine controls prolonged status epilepticus. Epilepsy Res. 2000; 42 ( 2–3 ): 117 – 22.
dc.identifier.citedreferenceBetjemann JP, Josephson SA, Lowenstein DH, Guterman EL. Emergency medical services protocols for generalized convulsive status epilepticus. JAMA. 2019; 321 ( 12 ): 1216 – 7.
dc.identifier.citedreferenceSpatola M, Alvarez V, Rossetti AO. Benzodiazepine overtreatment in status epilepticus is related to higher need of intubation and longer hospitalization. Epilepsia. 2013; 54 ( 8 ): 99 – 102.
dc.identifier.citedreferenceStewart WA, Harrison R, Dooley JM. Respiratory depression in the acute management of seizures. Arch Dis Child. 2002; 87 ( 3 ): 225 – 6.
dc.identifier.citedreferenceGreenblatt DJ, Divoll M, Harmatz JS, Shader RI. Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. J Pharm Sci. 1982; 71 ( 2 ): 248 – 52.
dc.identifier.citedreferenceLau SWJ, Slattery JT. Absorption of diazepam and lorazepam following intranasal administration. Int J Pharm. 1989; 54: 171 – 4.
dc.identifier.citedreferenceWermeling DPH, Miller JL, Archer SM, Manaligod JM, Rudy AC. Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration. J Clin Pharmacol. 2001; 41: 1225 – 31.
dc.identifier.citedreferenceMeierkord H, Boon P, Engelsen B, Göcke K, Shorvon S, Tinuper P, et al. EFNS guideline on the management of status epilepticus. Eur J Neurol. 2006; 13 ( 5 ): 445 – 50.
dc.identifier.citedreferenceBrophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012; 17 ( 1 ): 3 – 23.
dc.identifier.citedreferenceGlauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence‐based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016; 16 ( 1 ): 48 – 61.
dc.identifier.citedreferenceKapur J, Elm J, Chamberlain JM, Barsan W, Cloyd J, Lowenstein D, et al. Randomized trial of three anticonvulsant medications for status epilepticus. N Engl J Med. 2019; 381 ( 22 ): 2103 – 13.
dc.identifier.citedreferenceChamberlain JM, Kapur J, Shinnar S, Elm J, Holsti M, Babcock L, et al. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double‐blind, responsive‐adaptive, randomised controlled trial. Lancet. 2020; 395: 1217 – 24.
dc.identifier.citedreferenceLanger JE, Fountain NB. A retrospective observational study of current treatment for generalized convulsive status epilepticus. Epilepsy Behav. 2014; 2014 ( 37 ): 95 – 9.
dc.identifier.citedreferenceAlvarez V, Lee JW, Drislane FW, Westover MB, Novy J, Dworetzky BA, et al. Practice variability and efficacy of clonazepam, lorazepam, and midazolam in status epilepticus: a multicenter comparison. Epilepsia. 2015; 56 ( 8 ): 1275 – 85.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
epi16825_am.pdf
Size:
389.9KB
Format:
PDF
View/Open
Name:
epi16825.pdf
Size:
1.113MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.